Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease

Phase 2TerminatedNCT00500500

Ipsen40 enrolled

Overview

The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Alzheimer Disease

Interventions

EGb 761® (Tanakan®)DRUG

Eligibility

Sex: ALLMin age: 50 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * female or male of 50 to 85 years old with a care giver * Mini Mental Status (MMS) test between 16 to 26 inclusive * Clinical Dementia Rating (CDR) test inferior or equal to 1 * National Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test positive for an Alzheimer's disease * Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test positive for dementia Exclusion Criteria: * patient already treated by medicines which could interfere with the study * low level of vitamin B12 and folate which are considered as clinically relevant * clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness; evolutive cancer, neurological illness, blood illness….)

Locations (1)

Hôpital La Timone

Marseille, France

Outcomes

Primary Outcomes

Effect of EGb 761® on the ratio of the isoform of the protein precursor of beta amyloid platelets.

Time frame: Every visit

Secondary Outcomes

Efficacy of EGb 761® on the cognitive functions and safety of EGb 761® at a dosage of 240 mg per day

Time frame: Every visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.